International Journal of Drug Delivery Technology
Volume 14, Issue 2

Preparation and Evaluation of Ficus racemosa Extract Transdermal Gel for Antimicrobial and Anti-inflammatory Activity

Monika Sharma1*, Jyoti Gupta1, Prabhjot Singh2

1IEC School of Pharmacy, IEC University, Baddi, Himachal Pradesh, India.

2Ch. Devi Lal College of Pharmacy, Bhagwangarh, Yamunanagar, Haryana, India. 

Received: 19th January, 2024; Revised: 14th March, 2024; Accepted: 09th May, 2024; Available Online: 25th June, 2024 

ABSTRACT

Background: Ficus racemosa (FR) belongs to the Moraceae family having different pharmacological activities. The primary aim of the researchers was to examine how varying polymer concentrations affect the outcome, additionally nature of penetration enhancers on microbial growth inhibition, and the protein denaturation inhibition capability of F. racemosa extract (FRE).

Method: FRE has been prepared by a simple maceration process. By performing an antimicrobial assay procedure and in-vitro protein denaturation inhibition method, the antimicrobial and protein denaturation capability of the extract has been confirmed. Furthermore, 12 formulations of transdermal gel were developed with polymer (carbopol 934), which was used at non-identical concentrations (1, 1.5, 2, 2.5%) along with three dissimilar kinds of penetration enhancers, i.e., Tween 80, oleic acid, thioglycolic acid at the same concentration (1%). Transdermal gels have been prepared by a dispersion method & evaluated by physical parameters, viscosity, spreadability, pH, skin irritation, drug content, and in-vitro study with Franz diffusion cell.

Result: Formulation B3 showed the best results, having a polymer concentration of 1.5% and Tween 80 as a penetration enhancer.

Keywords: Denaturation, Penetration enhancer, Microbial inhibition, Drug content.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.69

How to cite this article: Sharma M, Gupta J, Singh P. Preparation and Evaluation of Ficus racemosa Extract Transdermal Gel for Antimicrobial and Anti-inflammatory Activity. International Journal of Drug Delivery Technology. 2024;14(2):1059-1065.

REFERENCES

  1. Bhowmik D, Chiranjib, Chandira M, Jayakar B, Sampath KP. Recent advances in transdermal drug delivery system. Int. J Pharm Tech Res. 2010; 2(1):68-77.
  2. Kumar A, Pullankandam N, Prabhu SL, Gopal V. Transdermal drug delivery system: an overview. Int. J Pharm Sci. Review Res. 2010;3(2):49-54.
  3. Divya A, Rao MK, Gnanprakash K, Sowjanya A, Vidyasagar N, Gobinath A review on the current scenario of transdermal drug delivery system. Int. J Res. Pharm Sci. 2012;3(4):494-502.
  4. Patel D, Sunita A, Parmar B, Bhura N, Transdermal Drug Delivery System: A Review, the Pharma Innovation. 2012; 1(4):66-75. https://doi.org/10.31638/IJPRS.V1.I1.00018
  5. Rani S, Saroha K, Syan N, Mathur P. Transdermal patches a successful tool in transdermal drug delivery Plegia Res. Lib. 2011;2(5):17-29.
  6. Dhawan S, Aggarwal Development, fabrication and evaluation of transdermal drug delivery system- a review. Pharm info.net. 2009:1-25.
  7. Patel D, Chaudhary SA, Parmar B, Bhura N. Transdermal drug delivery system: a The Pharm Innovation. 2012;1(4):66- 75.
  8. Schoellhammer, C.M.; Blankschtein, D.; Langer, R. Skin Permeabilization for Transdermal Drug Delivery: Recent Advances and Future Expert Opin. Drug Deliv. 2014; 11:393-407. https://doi.org/10.1517/17425247.2014.875528
  9. Karbhari V N, Tanuja W. Transdermal drug delivery system: A review. World J Pharm Res. 2016; 5(9):1733-42.
  10. Narin,G. J. 1997. Encyclopedia of Pharmaceutical Technology, Marcel Decker, New york. Alberti,I., Grenier, , Kraus, H., Carrara, D.N. 2005. Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery.ExpertOpin Drug Delivery.2, 935-50. Tanwar and Sachdeva, IJPSR, 2016; Vol. 7(6): 2274-2290. E-ISSN:0975-8232; P-ISSN:2320-5148
  11. Kalia YN, Naik A, Garrison J, Guy Iontophoretic drug delivery. Adv Drug Deliv Rev. 2004;56(5):619–58.
  12. Machet L, Boucaud A. Phonophoresis: efficiency, mechanisms and skin tolerance. Int J Pharm. 2002;243(1–2):1–15.
  13. Ogura M, Paliwal S, Mitragotri Low-frequency sonophoresis: current status and future prospects. Adv Drug Deliv Rev. 2008;60(10):1218–23.
  14. Thong, HY, Zhai, and Maibach, HI. Percutaneous penetration enhancers: an overview. Skin pharmacology and physiology.2007; 20 (6):272–82.
  15. Sloan, , Wasdo, SC., Rautio, J. Design for optimized topical delivery: prodrugs and a paradigm change. Pharm Res.2006; 23(12):2729–47.
  16. Rothbard, JB., Garlington,S., Lin Q., Kirschberg T., Kreider , McGrane PL. et al. Conjugation of arginine oligomers to cyclosporine A facilitates topical delivery and inhibition of inflammation.Nat Med. 2000;6(11):1253–7.
  17. Zhao YL, Murthy SN, Manjili MH, Guan L, Sen A, Hui SW. Induction of cytotoxic T- lymphocytes by electroporation- enhanced needle- f ree skin Vaccine. 2006;24(9):1282–90.
  18. Bramson J, Dayball K, Evelegh C, Wan Y, Page D, Smith A. Enabling topical immunization via microporation: a novel method fornpain-free and needle-free delivery of adenovirus-based Gene Ther. 2003;10(3):251–60.
  19. Hiren Patel, Darshan G. Trivedi, Anand K. Bhandari, Dushyant A. Shah. Penetration enhancers for transdermal drug deliverysystem: A review www.ijpijournals.comVol 1: 2 (2011) IJPI.
  20. Funke, AP., Schiller, R., Motzkus, HW., Gunther, C., Muller, RH., Lipp, Transdermal delivery of highlylipophilic drug: in-vitro fluxes of antiestrogen permeation enhancers, and solvents from liquid formation.Pharm Res 2002; 19: 661-668.
  21. Goodman, M., Barry, BW. Lipid-protein partitioning theory of skin enhancer activity. Finit dose technique.Int J Pharm 1989; 57: 29-40.
  22. Chien, W., Xu, H., Chiang, C.C. and Hung, Y.C. Transdermal controlled administration of indomethacin: I.Enhancement of skin permeability. Pharm. Rcs. 1998; 5:103- 106.
  23. Delly Ramadon1,2 · Maeliosa T. C. McCrudden3 ;Aaron J. Courtenay4 · Ryan F. Donnelly, Penetration enhancers for transdermal drug delivery system: A review, ISSN 2229 – 6832,
  24. Syed Talha Pasha1, Roshan. S2* Formulation and Evaluation of Terbulus terrestris Topical gel for Wound healing activity ; S.C.B., ISSN: 1583-6258, Vol.25, Issue 4, 2021, Pages. 19213-19224.
  25. Priya Mohan N.1*, Suma Jayaram2, Sanitha Kuriachan1 Study of anti- inflammatory activity of Ficus racemosa linn stem bark, DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20210552.
  26. Khan N, Sultana Chemomodulatory effect of Ficus racemosa extract against chemically induced renal carcinogenesis and oxidative damage response in Wistar rats. Life Sci. 2005;77:1194– 210.
  27. Ahmed F, Hudeda S, Urooj A. Anti-hyperglycemic activity of Ficus racemosa barks in type 2 diabetic J Diabetes. 2011;3:318–9.
  28. Rao RB, Anupama K, Swaroop KRLA, Murugesan T, Pal M, Mandal Evaluation of antipyretic potential of Ficus racemosa bark. Phytomedicne. 2002;9:731–3.
  29. Vitus Nyigo, Xolani Peter, Faith Mabiki, Hamisi M. Malebo, Robinson H. Mdegela, Gerda Fouche,Isolation and identification of euphol and β-sitosterol from the dichloromethane extracts of Synadenium glaucescens, ISSN 2230-480X JPHYTO 2016;5(3): 100-104.
  30. Subhash C. Mandal,1 B. P. Saha2 and M. Pal2, Studies on Antibacterial Activity of Ficus racemosa Leaf Extract, phytotherapy research,Phytother. Res. 14, 278–280 (2000)
  31. Tanvi Pingale1,*, Pallavi Duse2, Sunita Ogale3, Antibacterial and Antifungal Approaches of Ficus racemosa, Pharmacogn J. 2019; 11(2): 355-357
  32. Dharmadeva, et al.: Anti-inflammatory activity of Ficus racemosa bark – An in-vitro study, DOI: 4103/ayu.AYU_27_18
  33. Priya Mohan B. N.1*, Suma Jayaram2, Sanitha Kuriachan1, Study of anti-inflammatory activity of Ficus racemosa linn stem bark extract in albino rats, DOI:https://dx.doi.org/10.18203/2319-2003. ijbcp20210552, 2021 Mar;10(3):231-237.
  34. Priya Mohan B. N.1*, Suma Jayaram2, Sanitha Kuriachan1, Study of anti-inflammatory activity of Ficus racemosa linn stem bark extract in albino rats, DOI: https://dx.doi.org/10.18203/2319-2003.
  35. Araújo et al. Anti-inflammatory and cytotoxic activities of the extracts, fractions, and chemical constituents isolated from Luehea ochrophylla Mart, https://doi.org/10.1186/s12906- 019- 2701-7
  36. Klaus F, Analytical profile of drug substances and excipients.vol-10, Academic press. Inc; 1981. p. 405-435.
  37. United States Rockville.MD: USP Convention Inc .32 revision, NF 27; 2009.
  38. Hussien ME, Ibrahim MM, Issa YM , Fatma MG, Barakat Application of TLC- densitometry, first derivative and ratio derivative spectrophotometry for the determination of eprosartan mesylate and hydrochlorothiazide in pharmaceutical preparations. Int. J. Drug Dev. & Res. 2011; 3 (4): 168-177
  39. Kashyap et al, Formulation and Evaluation of Transdermal Topical Gel of Ibuprofen, Journal of Drug Delivery & Therapeutics. 2020; 10(2):20-25.
  40. Randa Mohammed Zaki 1,2, Mohamed Ibrahim 3,4, Doaa H. Alshora 3,* and Amal El Sayeh Abou El Ela 3,5; Formulation and Evaluation of Transdermal Gel Containing Tacrolimus- Loaded Spanlastics: In-vitro, Ex Vivo and In Vivo Studies R, Polymers 2022, 14(8), 1528; https://doi.org/10.3390/polym14081528.